

*Lilly***Fax**

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285  
U.S.A.

**To: Assistant Commissioner For Patents**

RECEIVED  
CENTRAL FAX CENTER

**Company:** U.S. Patent and Trademark Office**From:** R. Craig Tucker

MAY 03 2004

**Fax:** 9-1-703-872-9306**Fax:** (317) 276-3861**OFFICIAL****Date:** May 3, 2004**Total Pages:** 4

If you have any questions concerning the content of this message, please call: R. Craig Tucker  
(317) 433-9829

**RE:** Patent Application No. 10/031,414  
Filed: May 29 2002  
Applicant: Briner et al.  
Examiner: Thomas C. McKenzie  
Art Unit 1624

Attorney Docket No. X-11593

Information Disclosure Statement

**CONFIDENTIALITY NOTICE**

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect) and return the original message to us at the above address via U.S. Postal Service.

**Answers That Matter.**

## CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at facsimile number:  
1-703-872-9306 on May 3, 2004.

By Date May 3, 2004

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED  
CENTRAL FAX CENTER

MAY 03 2004

OFFICIAL

Applicants:	Briner et al.	)	
Serial No.:	10/031,414	)	
Filed:	May 29, 2002	)	Group Art Unit:
Title:	SEROTONERGIC BENZOFURANS)	)	1624
Docket No.:	X11593	)	Examiner:
		)	Thomas C. McKenzie

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Introductory Comments

In reviewing our files on the above referenced case, it has come to our attention that we do not have an initialed copy of our previously submitted Information Disclosure Statement and Form 1449. In a telephone conversation with the Examiner, we were instructed to forward a copy of what was filed, as proof of such submission, and the Examiner would consider the Statement.

Applicants submit the attached copy of the Statement previously made and request that references be initialed by the Examiner as having been considered. It is noted that all the references on the Form 1449 were previously cited in the published International Search Report for this PCT application and were also cited and fully considered in the Written Opinion and favorable IPER and therefore were before the Examiner during the prosecution of the application.

Respectfully submitted,

  
R. Craig Tucker  
Attorney for Applicants  
Registration No. 45,165  
Phone: 317-433-9829

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

May 3, 2004

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

By: Hinda M. DurbinDate: August 28, 2002PATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Briner, et al.

Serial No. : 10/031,414

Filed : May 29, 2002

For : SEROTONERGIC BENZOFURANS

Docket No. : X-11593

Group Art Unit:  
1624

Examiner:

INFORMATION DISCLOSURE STATEMENT**COPY**

Assistant Commissioner for Patents

Washington, D.C. 20231


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation in an Application" on a modified Form PTO-1449 and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



R. Craig Tucker  
Attorney for Applicants  
Registration No. 46,165  
Phone: 317-433-9829

Eli Lilly and Company  
Patent Division/RCT  
Lilly Corporate Center  
Indianapolis, IN 46285

Aug. 27, 2002

FORM PTO 1449 (modified)		Atty. Docket No. X-11593		Serial No 10/031.414			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Briner, et al.					
		Filing Date 05/29/2002		Group 1624			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub- class	Translation yes no
	BA	EP 0 006 524 A	01/09/90	PCT			
	BB	EP 0 189 612 A	08/06/86	PCT			
	BC	EP 0 398 413 A	11/22/90	PCT			
	BD	EP 0 982 304 A	03/01/00	PCT			
	BE	WO 00 00203 A	01/06/00	PCT			
	BF	WO 00 00196 A	01/06/00	PCT			
	BG						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	CA	Patent Abstracts of Japan: Vol. 016 no. 071 (c-0913) (1992-02-21) & JP 03 264583 A (DAI ICHI SEIYAKU CO LTD), (1991-11-25) abstract					
	CB	McGarry D.G. et al.: "Benzofuran based PDE4 inhibitors: BIOORGANIC & MEDICINAL CHEMISTRY., Vol. 7, no. 6, 1999 pgs 1131-1139, XP000978427 ELSEVIER SCIENCE LTD., GB ISSN: 0968-896					
	CC						
	CD						
	CE						
	CF						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

COPY